5-(methylsulfonylamino)-1-indanone | 270074-52-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-(methylsulfonylamino)-1-indanone
• 英文别名: N-(1-Oxo-indan-5-yl)-methanesulfonamide；5-methanesulfonamido-1-indanone；N-(1-oxo-2,3-dihydroinden-5-yl)methanesulfonamide
• CAS: 270074-52-7
• 化学式: C₁₀H₁₁NO₃S
• 分子量: 225.268
• InChiKey: UWDDYEVYLGVXLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(methylsulfonylamino)-1-indanone 在 吡啶 、 盐酸羟胺 作用下， 反应 3.0h， 以95%的产率得到5-(methylsulfonylamino)-1-indanone oxime
  参考文献：
  名称：

  Conformationally constrained analogues of N′-(4-tert-butylbenzyl)-N-(4-methylsulfonylaminobenzyl)thiourea as TRPV1 antagonists

  摘要：

  A series of bicyclic analogues having indan and tetrahydronaphthalene templates in the A-region were designed as conformationally constrained analogues of our previously reported potent TRPV1 antagonists (1, 3). The activities for rat TRPV1 of the conformationally restricted analogues were moderately or markedly diminished, particularly in the case of the tetrahydronaphthalene analogues. The analysis indicated that steric constraints at the benzylic position in the bicyclic analogues may be an important factor for their unfavorable interaction with the receptor. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.02.026
• 作为产物：
  描述：

  5-氨基氢化茚-1-酮 、 甲基磺酰氯 在 吡啶 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 以42%的产率得到5-(methylsulfonylamino)-1-indanone
  参考文献：
  名称：

  HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS

  摘要：

  该发明提供了一类新颖的化合物，包括含有这些化合物的药物组合物，以及使用这些化合物来治疗或预防与TPO活性异常或失调相关的疾病或障碍的方法，尤其是涉及血小板减少症的疾病或障碍。

  公开号：

  US20090075996A1

文献信息

• HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS
  申请人：Alper Phillip B.

  公开号：US20090075996A1

  公开（公告）日：2009-03-19

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.

  该发明提供了一类新颖的化合物，包括含有这些化合物的药物组合物，以及使用这些化合物来治疗或预防与TPO活性异常或失调相关的疾病或障碍的方法，尤其是涉及血小板减少症的疾病或障碍。
• Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
  申请人：Pharmacia Corporation

  公开号：US20030032657A1

  公开（公告）日：2003-02-13

  Methods of treating cyclooxygenase-2 mediated disorders comprising administering to a subject a therapeutically effective amount of one or more fluoro-substituted benzenesulfonyl compounds corresponding to Formula I: 1 wherein A, X, n, R 1 , R 2 , and R 3 are as described in the specification, and novel fluoro-substituted benzenesulfonyl compounds within Formula I.

  治疗环氧合酶-2介导的疾病的方法包括向受试者施用与化学式I:1相对应的一种或多种氟代苯磺酰化合物的治疗有效剂量，其中化学式I中的A、X、n、R1、R2和R3如规范中所述，并且包括化学式I中的新型氟代苯磺酰化合物。
• 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation
  申请人：Pharmacia Corporation

  公开号：US20020183362A1

  公开（公告）日：2002-12-05

  Methods of treating cyclooxygenase-2 mediated disorders comprising administering to a subject a therapeutically effective amount of one or more 2-fluorobenzenesulfonyl compounds corresponding to Formula I: 1 wherein A, R 1 , R 2 , and R 3 are as described in the specification, and novel 2 fluorobenzenesulfonyl compounds within Formula I.

  治疗环氧合酶-2介导的疾病的方法包括向受试者施用与公式I中对应的一种或多种2-氟苯磺酰化合物的治疗有效剂量：1其中A、R1、R2和R3如规范中所述，并且公式I内的新型2-氟苯磺酰化合物。
• PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES
  申请人：Gately Stephen

  公开号：US20070129331A1

  公开（公告）日：2007-06-07

  Novel compositions of silicon-substituted carboxylic acid-containing-nonsteroidal anti-inflammatory drugs, their preparation and use in methods for treating, preventing and/or reducing inflammation, pain, angiogenesis, and cortical dementias including Alzheimer's disease, inflammation-related cardiovascular disorders and cancer are described. The compositions and methods are effective at decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of non-selective carboxylate-containing-nonsteroidal anti-inflammatory drugs.

  本发明涉及硅取代羧酸类非甾体抗炎药的新型组合物，其制备和用于治疗、预防和/或减轻炎症、疼痛、血管生成和皮层痴呆症，包括阿尔茨海默病、与炎症相关的心血管疾病和癌症的方法。该组合物和方法对于减少或逆转由于非选择性羧酸类非甾体抗炎药的使用而导致的胃肠道、肾脏和其他毒性具有有效性。
• Heterotetracyclic compounds as TPO mimetics
  申请人：IRM LLC

  公开号：US08153671B2

  公开（公告）日：2012-04-10

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.

  本发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或调节TPO活性相关的疾病或障碍的方法，特别是涉及血小板减少症的疾病或障碍。